ETS-1 induces Sorafenib-resistance in hepatocellular carcinoma cells via regulating transcription factor activity of PXR

2018 ◽  
Vol 135 ◽  
pp. 188-200 ◽  
Author(s):  
Zhiyi Shao ◽  
Yibo Li ◽  
Wenjie Dai ◽  
Hui Jia ◽  
Yingshi Zhang ◽  
...  
2015 ◽  
Vol 466 (1) ◽  
pp. 115-121 ◽  
Author(s):  
Hyun Kook Cho ◽  
So Young Kim ◽  
Yi Yi Kyaw ◽  
Aye Aye Win ◽  
Seung-Hoi Koo ◽  
...  

HBx protein is encoded by HBV and plays a critical role in hepatocarcinogenesis. In the present study we show that HBx activates the expression of the CREBH transcription factor and interacts with the activated CREBH. CREBH activation by HBx may result in cell proliferation.


2021 ◽  
Vol 11 ◽  
Author(s):  
Qiyu Jiang ◽  
Yan Ma ◽  
Jingjing Han ◽  
Jingdong Chu ◽  
Xuemei Ma ◽  
...  

The MDM2 binding protein (MTBP) has been considered an important regulator of human malignancies. In this study, we demonstrate that the high level of MTBP’s endogenous expression is correlated with poor prognosis of advanced hepatocellular carcinoma (HCC) patients who received sorafenib. MTBP interacted with the Pregnane X receptor (PXR) and enhanced the transcription factor activity of PXR. Moreover, MTBP enhanced the accumulation of PXR in HCC cells’ nuclear and the recruitment of PXR to its downstream gene’s (cyp3a4’s) promoter region. Mechanically, the knockdown of MTBP in MHCC97-H cells with high levels of MTBP decelerated the clearance or metabolism of sorafenib in HCC cells and led to the resistance of HCC cells to sorafenib. Whereas overexpression of MTBP in in MHCC97-L cells with low levels of MTBP showed the opposite trend. By establishing the interaction between MTBP and PXR, our results indicate that MTBP could function as a co-activator of PXR and could be a promising therapeutic target to enhance the sensitivity of HCC cells to molecular targeting agents.


Sign in / Sign up

Export Citation Format

Share Document